Fleisher A S, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine O C, Yin J, Zou T T, Abraham J M, Kong D, Wilson K T, James S P, Herman J G, Meltzer S J
Department of Medicine, University of Maryland School of Medicine and Baltimore Veterans Affairs Hospital, 21201, USA.
Cancer Res. 2000 Sep 1;60(17):4864-8.
Twelve to 15% of sporadic colorectal cancers display defective DNA mismatch repair (MMR), manifested as microsatellite instability (MSI). In this group of cancers, promoter hypermethylation of the MMR gene hMLH1 is strongly associated with, and believed to be the cause of, MSI. A subset of colorectal neoplastic lesions arising in inflammatory bowel disease (IBD) is also characterized by MSI. We wished to determine whether hMLH1 hypermethylation was associated with diminished hMLH1 protein expression and MSI in IBD neoplasms. We studied 148 patients with IBD neoplasms, defined as carcinoma or dysplasia occurring in patients with ulcerative colitis or Crohn's disease. MSI was evaluated using multiplex fluorescent PCR to amplify loci D2S123, BAT-25, BAT-26, D5S346, and D17S250 in all cases. Lesions were characterized as high-frequency MSI (MSI-H) if they manifested instability at two or more loci, low-frequency MSI (MSI-L) if unstable at only one locus, or MS-stable (MSS) if showing no instability at any loci. Methylation-specific PCR was performed to determine the methylation status of the hMLH1 promoter region. hMLH1 protein expression was also evaluated by immunohistochemistry. Thirteen (9%) of 148 neoplasms arising in IBD were MSI-H, comprising 11 carcinomas and 2 dysplastic lesions. Sixteen additional lesions (11%) were MSI-L, comprising 11 carcinomas and 5 dysplastic lesions. The remaining 118 neoplasms (80%) were MSS. Six (46%) of 13 MSI-H, 1 (6%) of 16 MSI-L, and 4 (15%) of 27 MSS lesions showed hMLH1 hypermethylation (P = 0.013). Diminished hMLH1 protein expression in neoplastic cell nuclei relative to surrounding normal cell nuclei was demonstrated immunohistochemically in four of four (100%) hypermethylated lesions tested. In IBD neoplasia, hMLH1 promoter hypermethylation occurs frequently in the setting of MSI, particularly MSI-H. Furthermore, hMLH1 hypermethylation and MSI are strongly associated with diminished hMLH1 protein expression in IBD neoplasms. These findings suggest that hMLH1 hypermethylation causes defective DNA MMR in at least a subset of IBD neoplasms.
12%至15%的散发性结直肠癌存在DNA错配修复(MMR)缺陷,表现为微卫星不稳定性(MSI)。在这组癌症中,MMR基因hMLH1的启动子高甲基化与MSI密切相关,并且被认为是MSI的原因。炎症性肠病(IBD)中出现的一部分结直肠肿瘤性病变也具有MSI特征。我们希望确定hMLH1高甲基化是否与IBD肿瘤中hMLH1蛋白表达减少及MSI相关。我们研究了148例IBD肿瘤患者,这些肿瘤定义为溃疡性结肠炎或克罗恩病患者发生的癌或发育异常。所有病例均使用多重荧光PCR扩增位点D2S123、BAT - 25、BAT - 26、D5S346和D17S250来评估MSI。如果病变在两个或更多位点表现出不稳定性,则将其特征化为高频MSI(MSI - H);如果仅在一个位点不稳定,则为低频MSI(MSI - L);如果在任何位点均无不稳定表现,则为微卫星稳定(MSS)。进行甲基化特异性PCR以确定hMLH1启动子区域的甲基化状态。还通过免疫组织化学评估hMLH1蛋白表达。IBD中出现的148个肿瘤中有13个(9%)为MSI - H,包括11例癌和2例发育异常病变。另外16个病变(11%)为MSI - L,包括11例癌和5例发育异常病变。其余118个肿瘤(80%)为MSS。13个MSI - H病变中有6个(46%)、16个MSI - L病变中有1个(6%)以及27个MSS病变中有4个(15%)显示hMLH1高甲基化(P = 0.013)。在检测的4个(100%)高甲基化病变中,免疫组织化学显示肿瘤细胞核中hMLH1蛋白表达相对于周围正常细胞核减少。在IBD肿瘤形成中,hMLH1启动子高甲基化在MSI情况下经常发生,尤其是MSI - H。此外,hMLH1高甲基化和MSI与IBD肿瘤中hMLH1蛋白表达减少密切相关。这些发现表明,hMLH1高甲基化至少在一部分IBD肿瘤中导致DNA错配修复缺陷。